Post-hoc data from CheckMate 227 and CheckMate 9LA trials indicated that ipilimumab plus nivolumab achieved numerically improved survival and durable responses in KRAS-mutant NSCLC with concurrent STK11 or KEAP1 loss compared with PD-1 monotherapy (193). This evidence concerns the gene KRAS and non-small cell lung carcinoma.